Last reviewed · How we verify
NCT03843255: Go-DCM
Defining the Genetics, Biomarkers and Outcomes for Dilated Cardiomyopathy
trial testing Part 1: DCM Cohort in Dilated Cardiomyopathy in 2,000 participants. Participants enrolled and being followed up; not accepting new ones.
22 July 2027
Quick facts
| Lead sponsor | Imperial College London |
|---|---|
| Status | Active, enrolled |
| Study type | OBSERVATIONAL |
| Enrollment | 2,000 |
| Start date | 9 January 2020 |
| Primary completion | 22 July 2027 |
| Estimated completion | 16 June 2029 |
| Sites | 6 locations across United Kingdom |
Drugs / interventions tested
- Part 1: DCM Cohort
- Part 2: Heritable CV Diseases and Family Members
Conditions studied
- Dilated Cardiomyopathy — all drugs for Dilated Cardiomyopathy →
- Cardiovascular Diseases — all drugs for Cardiovascular Diseases →
Sponsor
Imperial College London
Who can join
Under 99, any sex, with Dilated Cardiomyopathy or Cardiovascular Diseases. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Finding new ways to diagnose and treat Dilated Cardiomyopathy (DCM) could improve the health and well-being of patients with this condition. The main aim of this research study is to help develop better ways of diagnosing and treating patients with DCM. The information that is collected may help develop tailored treatments for patients with this disease in the future. This research study will recruit patients with DCM from a number of centres across England and follow their health over a period of years. Patients will give some blood samples for a type of genetic test called whole genome sequencing (WGS) to look for genetic changes. Patients will also have a magnetic resonance imaging (MRI) scan of their heart to look for any changes in the heart such as scarring, and check their heart function. The aim of this study is to discover if using WGS and MRI can improve the diagnosis of DCM. Another aim of the study is to look at how genetic changes and scarring in the heart may affect the progress of the disease. Studying patients with DCM may also help the investigators learn more about diagnosing and treating other diseases of the heart. The second aim of this study is to see whether using WGS and MRI scanning can also be useful in other types of heart diseases which might be affected by genetic changes or scarring in the heart.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Association between coronary microvascular dysfunction and exercise capacity in dilated cardiomyopathy.
Dattani A, Marrow BA, Gulsin GS, Yeo JL, et al · · 2024 · cited 3× · PMID 39426603 · DOI 10.1016/j.jocmr.2024.101108
Verify or expand the search:
- PubMed search for NCT03843255
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Dilated Cardiomyopathy
Currently open trials in the same condition.
- NCT07241104 — A Study of AZD4063 in PLN R14del Dilated Cardiomyopathy · Phase 1 · recruiting
- NCT06250257 — Bromocriptine in Dilated Cardiomyopathy Among Women of Reproductive Age · Phase 3 · recruiting
- NCT06730464 — Image-Based Prediction of Ventricular Tachycardia Events in Non-ischemic Cardiomyopathy · recruiting
- NCT06236022 — The Effects of Sirolimus in Patients With Dilated Cardiomyopathy Infected With Kaposi Sarcoma-associated Virus · Phase 4 · recruiting
- NCT05837143 — Myocardial Telomere Recapping Study for Dilated Cardiomyopathy · EARLY_PHASE1 · active not recruiting
Other Imperial College London trials
Trials by the same sponsor.
- NCT06035861 — Endothelial Cell Activation and Total Pulmonary Resistance in PAH · NA · not yet recruiting
- NCT07397455 — Development of a Controlled Human Infection Model for Assessment of SARS-CoV-2 Omicron Subvariants · Phase 1 · not yet recruiting
- NCT07422532 — A Multi-centre Trial to Assess the Efficacy and Safety of the Omnipod 5 System in People With Type 2 Diabetes Undergoing · NA · not yet recruiting
- NCT07389031 — Maralixibat for Intrahepatic Cholestasis of Pregnancy · Phase 2 · not yet recruiting
- NCT07358897 — Gender Affirming Hormone Therapy and Immune Function in Trans Individuals - The GIFT Study · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03843255 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Imperial College London
- Last refreshed: 27 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03843255.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing